Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/48

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/012292PERIPHERAL BLOOD TCR MARKER FOR PANCREATIC CANCER, AND DETECTION KIT AND USE THEREOF
WO 20.01.2022
Int.Class G01N 33/574
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
Appl.No PCT/CN2021/101981 Applicant CHENGDU EXAB BIOTECHNOLOGY CO., LTD Inventor ZHANG, Zhixin
Provided are a peripheral blood TCR marker for pancreatic cancer, and a detection kit and the use thereof. The marker comprises at least one protein, the sequences of which are shown as SEQ ID NO. 1-100. The method is performed on the basis of a high-throughput sequencing method, wherein only a small amount of peripheral blood needs to be collected to extract RNA; a sample is treated to establish an immune map library; high-throughput sequencing and TCR data analysis are carried out to determine a characteristic TCR sequence in peripheral blood of pancreatic cancer; and the test result of a sample to be tested is then compared with the characteristic TCR sequence so as to determine whether pancreatic cancer is present or not.
2.WO/2022/013762METHODS AND KITS FOR THE DIAGNOSIS OF LUNG CANCER
WO 20.01.2022
Int.Class G01N 33/574
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
Appl.No PCT/IB2021/056326 Applicant PINTO, Aldo Inventor PINTO, Aldo
The present invention relates to a method for the diagnosis and/or to monitor the development and/or to provide a prognosis on the development of lung cancer in an individual, including the detection of the expression levels of the isoform 4 of the human caspase-4 protein in biological samples. The present invention further relates to a kit and reagents for the detection of the expression levels of said isoform 4, as well as a compound inhibitor of said isoform 4 for use in the treatment and/or prevention of lung cancer.
3.WO/2022/014512METHOD AND DEVICE FOR DETERMINING KETOSIS MORBIDITY
WO 20.01.2022
Int.Class G01N 19/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
19Investigating materials by mechanical methods
Appl.No PCT/JP2021/026065 Applicant NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION Inventor NAKAKUBO Ryoh
The present invention addresses the problem of making it possible to conveniently determine, in the field, etc., ketosis morbidity and/or the possibility of ketosis morbidity in an animal. The present invention also addresses the problem of providing a device for performing said determination. A method for determining ketosis morbidity according to an embodiment of the present invention comprises presenting a gas generated from a body fluid collected from an animal (non-human) to a gas detection means, and using the response of the gas detection means to the gas generated from the body fluid to determine ketosis morbidity in the animal on the basis of the composition of the gas generated from the body fluid.
4.WO/2022/014707TRPV4 INHIBITOR AS THERAPEUTIC DRUG FOR EYE DISEASE
WO 20.01.2022
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
Appl.No PCT/JP2021/026829 Applicant RAQUALIA PHARMA INC. Inventor OHARA Kentaro
The present invention relates to the use of a compound having TRPV4 inhibitory activity, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing these, in the manufacture of a pharmaceutical product for the prevention or treatment of retinal disease that accompanies vascular disorders or cellular disorders. Further, the invention relates to a method of preventing or treating the aforementioned diseases, involving administering said compound or a pharmaceutical composition containing the same to a human or animal. Said compound, pharmaceutically acceptable salt thereof, or pharmaceutical composition containing these may be used in combination with one or more second active drugs. The invention relates to a kit and a pharmaceutical composition, used for the prevention or treatment of the aforementioned diseases and containing a compound having TRPV4 inhibitory activity or a pharmaceutically acceptable salt thereof. The invention further relates to a marker for diagnosing diseases usefully treated by said compound, and a method for screening drugs that prevent or treat the aforementioned diseases.
5.WO/2022/015532COMPOSITIONS AND METHODS FOR DETECTING GENE FUSIONS OF RAD51AP1 AND DYRK4 AND FOR DIAGNOSING AND TREATING CANCER
WO 20.01.2022
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Appl.No PCT/US2021/040463 Applicant UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor WANG, Xiaosong
Provided herein are compositions and methods for detecting RAD51AP1-DYRK4 fusions in a subject or tissue. In some embodiments, the subject or tissue is treated with an MEK inhibitor when a RAD51AP1-DYRK4 fusion is detected therein. Accordingly, included herein are methods for treating cancer in a subject using an MEK inhibitor and for identifying subjects that will be responsive to MEK inhibitor therapy.
6.WO/2022/015922HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
WO 20.01.2022
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/US2021/041737 Applicant THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor LEVIN, Noam
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with valine. The TCRs may recognize G12V RAS presented by an HLA-DR heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
7.WO/2022/011466DUAL FUNCTION SURFACE FOR CELL CAPTURE AND SPREADING
WO 20.01.2022
Int.Class C07K 17/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
17Carrier-bound or immobilised peptides; Preparation thereof
Appl.No PCT/CA2021/050968 Applicant THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY Inventor A. HOESLI, Corinne
There is provided a surface functionalized with cross linking groups adapted to receive antibodies and/or fragments thereof. The surface has an antibody binding biomolecule having a linker region which is covalently crosslinked to functional groups and an antibody binding region. The surface also has a cell interacting biomolecule having a linker region which is covalently crosslinked to functional groups of the surface and a cell interacting region that imparts functional attributes including cell adhesion, spreading, proliferation, differentiation and/or a functional response. The two biomolecules are present in independently controlled concentrations and have similar small molecular weights.
8.WO/2022/012291PERIPHERAL BLOOD TCR MARKER FOR BREAST CANCER AND DETECTION KIT AND APPLICATION THEREOF
WO 20.01.2022
Int.Class G01N 33/574
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
Appl.No PCT/CN2021/101961 Applicant CHENGDU EXAB BIOTECHNOLOGY CO., LTD Inventor ZHANG, Zhixin
Disclosed in the present invention are a peripheral blood TCR marker for breast cancer and a detection kit and an application thereof, the marker comprising at least one of the proteins shown in SEQ ID NO.1-100. The present invention is based on a high throughput sequencing method, and only a small amount of peripheral blood needs to be taken; RNA is extracted, an immunoassay library is established by means of processing the samples, and high throughput sequencing and TCR data analysis are performed, first determining characteristic TCR sequences in breast cancer peripheral blood, and then comparing the test result of a sample to be tested with the characteristic TCR sequences to determine whether there is breast cancer. The present invention can simultaneously compare a large number of breast cancer-specific TCR sequences, having higher specificity and accuracy compared to individual detection of one or several markers, and thereby improving diagnosis efficiency.
9.WO/2022/013176SELF-MIXING INTERFERFEROMETRY FOR ABSORPTION OR COLOR DETECTION AND APPLICATION IN LATERAL FLOW TESTING
WO 20.01.2022
Int.Class G01B 9/02
GPHYSICS
01MEASURING; TESTING
BMEASURING LENGTH, THICKNESS OR SIMILAR LINEAR DIMENSIONS; MEASURING ANGLES; MEASURING AREAS; MEASURING IRREGULARITIES OF SURFACES OR CONTOURS
9Instruments as specified in the subgroups and characterised by the use of optical measuring means
02Interferometers
Appl.No PCT/EP2021/069387 Applicant AMS AG Inventor LOUS, Erik Jan
It is proposed to use self-mixing interferometry for determining an absorption. The monitoring device for use in lateral flow testing for detecting presence or amount of an analyte (1) in a liquid (L) comprises a housing, the housing comprising a carrier holder for holding a carrier (10) for transport of the liquid (L); at least a first light source (41) which is a resonant-cavity light source having a cavity (C); and an evaluation unit (50), operationally connected to at least the first light source (41) for detecting a measurement signal. The first light source (41) is structured and arranged to illuminate with light a test range in a test area (13) of a carrier (10) held in the carrier holder; and to couple back into the cavity (C) of the first light source (41) a portion of the light coming back from the test range (13).
10.WO/2022/013551NANOPORE SENSING DEVICE
WO 20.01.2022
Int.Class G01N 33/487
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
483Physical analysis of biological material
487of liquid biological material
Appl.No PCT/GB2021/051806 Applicant OXFORD NANOPORE TECHNOLOGIES LIMITED Inventor XIE, Ping
A nanopore sensing device comprises a planar structure provided with plural fluidic passages extending between the first and second chambers. The planar structure supports nanopores in membranes across respective passages and sensor electrodes are arranged to sense a fluidic electrical potential in respective passages between the nanopores and the second chamber. The passages comprise planar fluidic resistor portions between the sensor electrode and the second chamber, the planar fluidic resistor portions extending in a planar direction of the planar structure and being configured to form a fluidic resistor.